Evidence map›Paper›PMID 26279302›Full record

ArticleOncogene2016

Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer.

S Zhang, W-C Chung, K Xu

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 3 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 42 citations in OpenAlex.

  1. High IntratumoralInternational journal of molecular sciences · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Significant Roles of NotchMolecules (Basel, Switzerland) · 2022
    Review
  8. Article
  9. Loss ofLife science alliance · 2021
    Article
  10. Cancer Stem Cells,Cells · 2020
    Review
  11. Article
  12. Article
  13. Protein O-fucosylation: structure and function.Current opinion in structural biology · 2019
    Review
  14. Review
  15. Article
  16. Article
  17. KrasOncoscience · 2017
    Article
  18. Article
  19. Role of Notch signaling pathway in pancreatic cancer.American journal of cancer research · 2017
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

S ZhangCancer Institute, University of Mississippi Medical Center, Jackson, MS, USA.
W-C ChungCancer Institute, University of Mississippi Medical Center, Jackson, MS, USA.
K XuCancer Institute, University of Mississippi Medical Center, Jackson, MS, USA.
University of Mississippi Medical Center · USCentral South University · CN

Funding

Functional analysis of Manic Fringe in the claudin-low breast cancerR21CA175136 · NCI · UNIVERSITY OF MISSISSIPPI MED CTR · PI XU, KELI · 2013 to 2014
$344k
NCI NIH HHS R21 CA175136
6 · The paper itself

Abstract

Notch controls pancreatic differentiation during development and is reactivated in pancreatic cancer. In recent years, the importance of Notch signaling in pancreatic tumorigenesis has become increasingly evident; however, it remains unclear how Notch activities are regulated in this context. Here we report differential regulation of Notch receptors by Lunatic Fringe (Lfng), which encodes an O-fucosylpeptide 3-β-N-acetylglucosaminyltransferase known to modify epidermal growth factor repeats in the Notch extracellular domain, during pathogenesis of Kras-induced pancreatic ductal adenocarcinoma (PDAC). We show that Lfng is uniquely expressed in a subset of acinar cells in the adult pancreas. Deletion of Lfng in the Kras(LSL-G12D/+);Pdx1-Cre mouse model caused increased activation of Notch3 throughout PDAC initiation and progression, and Notch1 after the onset of disease, associated with marked upregulation of Notch target gene Hes1. Deletion of Lfng also resulted in accumulation of Aldh1-positive cell population. We found that loss of Lfng significantly accelerated Kras-initiated PDAC development and shortened survival of the PDAC mice. Interestingly, Lfng-deficient tumors showed a propensity for a poorly differentiated state with features of epithelial-to-mesenchymal transition. Likewise, knockdown of LFNG in human PDAC cell lines caused elevated Notch activation, associated with either accelerated cell proliferation or expanded Aldh1-positive cell population. Deletion of Lfng resulted in downregulation of Tgfb1, Tgfb2 and Tgfbr2 expression in the wild-type pancreas at all ages examined, and in the Kras(LSL-G12D/+);Pdx1-Cre pancreas after PDAC onset, as well as reduced phospho-Smad2 levels in pancreatic tumors. We provide evidence that Lfng regulates transforming growth factor (TGF)-β signaling through Notch-mediated transcriptional repression of TGF-β pathway genes. Taken together, our results reveal a potent tumor-suppressive function for Lfng and crosstalk between Notch and TGF-β pathways in the pancreas, which provides new insight into initiation of PDAC and signals involved in disease progression.

Indexed as

CarcinogenesisAcinar CellsAnimalsCarcinoma, Pancreatic DuctalCell ProliferationDisease ProgressionGene Expression Regulation, NeoplasticGene Knockdown TechniquesGlycosyltransferasesHumansMiceNeoplastic Stem CellsPancreatic NeoplasmsProto-Oncogene Proteins p21(ras)Receptors, NotchSignal TransductionGlycosyltransferasesKRAS protein, humanLFNG protein, humanProto-Oncogene Proteins p21(ras)Receptors, NotchTumor Suppressor Proteins

Identifiers

PMID26279302
OpenAlexW2203908177

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.